Demonstrating Significant Correlation between Knee Function
Improvement and Cartilage Thickness Increase/Stabilization after TPX-100
OAKLAND, Calif.–(BUSINESS WIRE)–#arthritis–OrthoTrophix, Inc. (www.orthotrophix.com),
a privately-held biopharmaceutical company, announced today that the
company and its collaborators are presenting Phase 2 clinical study data
at the European Congress of Rheumatology in Madrid, Spain (June 12 –
15). The presentation, entitled “Improved Knee Physical Function
Correlates Significantly with TF Cartilage Thickness Increase after IA
TPX-100” is abstract THU0441.
Knee function, measured by the Knee injury and Osteoarthritis Outcome
Score (KOOS) and Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) at 6 and 12 months, was markedly improved
in TPX-100-treated knees compared to placebo-exposed knees. Twelve
months after TPX-100, knee function improvement was sustained and
correlated significantly with tibiofemoral cartilage thickness
stabilization or increase (p<0.01).
“Concordances between meaningful patient benefits and structural
benefits are critical for development of a disease-modifying drug for
osteoarthritis (DMOAD),” commented OrthoTrophix’ Chief Medical Officer,
Dr. Dawn McGuire. “These results complement recent findings that TPX-100
treatment reduces pathological bone shape change in the patella at 12
months, which correlates with a clinically meaningful decrease in the
frequency of knee pain. We believe TPX-100 has the potential to alter
the disease course of knee OA both clinically and structurally.”
About OrthoTrophix, Inc.
OrthoTrophix, Inc., based in Oakland, California, is a privately held
biopharmaceutical company focused on the development and
commercialization of revolutionary therapeutics for the treatment of
diseases and conditions involving the hard tissues. Founded by three
co-founders in 2011, the primary focus of OrthoTrophix has been
regeneration and repair of cartilage in the knee and other joints with
its novel proprietary compounds which promote formation of new cartilage
and bone tissues and thereby repair the respective defects.
This press release contains “forward-looking” statements. These
statements involve risks and uncertainties, which may cause results to
differ materially from those set forth in the statements. The
forward-looking statements include statements regarding product
development and cannot be guaranteed. OrthoTrophix undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events, or otherwise.
Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect OrthoTrophix’ business.
Contacts
Yoshi Kumagai
President and CEO
Tel: (510) 488-3824